Potential Predictors of Sensitivity to Pemetrexed as First-line Chemotherapy for Patients with Advanced Non-Squamous NSCLCs | Zendy

Yan-Yan Lu | Zendy; XinEn Huang | Zendy; Xü Lin | Zendy; De-Gan Liu | Zendy; Jie Cao | Zendy; Xueyan Wu | Zendy; Jin Liu | Zendy; Jin Xiang | Zendy

Open Access

Potential Predictors of Sensitivity to Pemetrexed as First-line Chemotherapy for Patients with Advanced Non-Squamous NSCLCs

Author(s) -

Yan-Yan Lu,

XinEn Huang,

Xü Lin,

De-Gan Liu,

Jie Cao,

Xueyan Wu,

Jin Liu,

Jin Xiang

Publication year - 2013

Publication title -

asian pacific journal of cancer prevention

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.512

H-Index - 75

eISSN - 2476-762X

pISSN - 1513-7368

DOI - 10.7314/apjcp.2013.14.3.2005

Subject(s) - pemetrexed , medicine , oncology , lung cancer , logistic regression , univariate analysis , chemotherapy , regimen , squamous carcinoma , multivariate analysis , carcinoma , cisplatin

Pemetrexed (PEM) is effective in first-line treatment for patients with non-squamous non-small cell lung cancer (NSCLC). However there are currently no definitive determinants to certify which patients could benefit from PEM. To improve the efficacy of PEM combined with platinum as first-line therapy for advanced non-squamous NSCLC, we conducted this retrospective study to detect potential determinants of this regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research